ticagrelor
ticagrelor: developed by 1 company · 3 clinical trials tracked · 1 FDA decision.
ticagrelor evidence translation
What we can confirm
1 FDA record · 3 tracked trials
What it means
What to watch
Prepared research question
How could ticagrelor → AZN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 2 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| ASTRAZENECA PLC (AZN) Untreated Follicular Lymphoma | Approved |
Clinical Trials (3)
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)
Primary endpoint: Primary safety endpoint - first major or clinically relevant non-major bleeding event, as defined by the ISTH
The Value of Screening for "High on Treatment Platelet Reactivity" in Patients Undergoing Lower Extremity Arterial Endovascular Interventions
Primary endpoint: Proportion of Participants With Primary Patency
Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel, Prasugrel, and Ticagrelor), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or, Prasugrel, or Ticagrelor When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects
Primary endpoint: Time-matched comparisons of IPA% (MPA) between treatments (i.e., Treatment A1 vs A2, Treatment B1 vs B2, and treatment C1 vs C2, treatments are defined below) following administration of ACT-246475 and its matching placebo.
FDA Decisions1 records
Frequently asked questions
Who is developing ticagrelor?
ticagrelor is being developed by ASTRAZENECA PLC.
How many clinical trials involve ticagrelor?
BioSniper tracks 3 clinical trials involving ticagrelor.
What is ticagrelor's latest FDA decision?
The most recent tracked FDA decision for ticagrelor is Approval for 1 INDICATIONS AND USAGE BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery dis, dated July 20, 2011.